Clinical Evidence: What the Published Trials Reveal
Mounjaro vs Wegovy: Understanding the Clinical Trial Evidence
When comparing Mounjaro vs Wegovy weight loss results, it's essential to examine the published clinical trial data that led to MHRA approval for both treatments. The landmark STEP programme demonstrated that patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks in the pivotal STEP 1 trial (Wilding et al., NEJM, 2021). Mounjaro's SURMOUNT trials showed impressive results through its dual GIP and GLP-1 receptor agonist mechanism, though direct head-to-head comparisons aren't available due to different trial designs and patient populations.
Both prescription-only medicines represent significant advances in obesity treatment, with each offering unique mechanisms of action that may suit different patient profiles. Wegovy works exclusively through GLP-1 receptor stimulation, whilst Mounjaro's tirzepatide targets both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously. This dual-hormone approach provides an additional pathway for appetite regulation and metabolic improvement, making the Mounjaro vs Wegovy comparison particularly relevant for patients seeking comprehensive weight management support through our GPhC-registered pharmacy services.
Mounjaro vs Wegovy Pricing: Complete UK Cost Breakdown
Understanding the financial investment for Mounjaro vs Wegovy treatment helps inform your decision between these evidence-based weight management options. Wegovy follows a structured dose escalation starting at £79.99 for the 0.25mg starter pen, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of £209.99 (2.4mg). Our Getting Started bundles offer convenience with the Intro Duo (0.25mg & 0.5mg) at £169.99, whilst our Ultimate Stability Trio provides three months of maintenance supply for £649.99. New customers benefit from our FIRST40 discount code, with returning customers using DOSE25 at checkout.
Mounjaro pricing follows its own escalation schedule, though specific costs vary based on dose requirements and individual treatment plans. Both treatments require careful dose titration under medical supervision, making bundle options particularly valuable for ensuring continuous supply throughout your weight management journey. The Mounjaro vs Wegovy cost comparison ultimately depends on your prescribed maintenance dose and treatment duration, with both options representing significant investment in evidence-based obesity management through our registered UK pharmacy services.
STEP Trial Results: Wegovy's Published Weight Loss Evidence
The comprehensive STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in weight management when prescribed alongside lifestyle modifications. STEP 1 demonstrated approximately 15% average weight loss at 68 weeks, whilst STEP 3 achieved around 16% when combined with intensive behavioural therapy support. The two-year STEP 5 data showed sustained weight loss of approximately 15.2%, indicating long-term effectiveness for patients who continue treatment.
Recent SELECT trial results revealed an additional benefit beyond weight management, with Wegovy demonstrating a 20% reduction in major cardiovascular events (HR 0.80) in eligible patients. This cardiovascular outcome data strengthens the clinical case for Wegovy in appropriate patient populations, though individual results may vary based on adherence to prescribed diet and exercise modifications alongside the medication regimen.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones involved in blood sugar regulation and appetite control. The medication works primarily by slowing gastric emptying, which promotes feelings of fullness after smaller meals and may reduce overall caloric intake throughout the day. GLP-1 receptors in the brain's appetite centres receive signals that help regulate food cravings and eating behaviours, supporting the dietary changes essential for successful weight management. Clinical studies suggest that this mechanism helps patients naturally reduce portion sizes whilst maintaining satisfaction from meals. The once-weekly injection schedule using the FlexTouch pen device provides consistent medication levels, supporting adherence to the prescribed treatment regimen alongside reduced-calorie diet and increased physical activity requirements.
EverydayMeds Ordering Process: Assessment to Delivery
Accessing Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for this prescription-only medicine safely and efficiently. Our qualified prescribers review your medical history, current medications, and weight management goals within our standard 3 working day timeframe, with express 24-hour review available for urgent requirements. Once approved, your Wegovy pens are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication stability throughout transport. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance whilst providing convenient access to this evidence-based treatment option. Payment processing includes automatic application of discount codes FIRST40 for new customers or DOSE25 for returning patients, making the entire process streamlined from assessment through to doorstep delivery.
Storage and Practical Considerations for Treatment Success
Proper storage of Wegovy ensures optimal medication effectiveness throughout your treatment journey, with unopened pens requiring refrigeration at 2-8°C until first use. Once removed from refrigeration, Wegovy offers superior room temperature stability compared to alternatives, maintaining potency for up to 6 weeks below 30°C versus Mounjaro's 21-day limitation. The FlexTouch pen delivery system provides precise dosing with clear visual confirmation of injection completion, whilst the mandatory dose escalation schedule (0.25mg to 2.4mg over 16 weeks) helps minimise gastrointestinal side effects commonly associated with GLP-1 treatments. Each pen contains four weekly doses, with used pens requiring safe disposal through household pharmaceutical waste programmes or return to participating pharmacies. Travel convenience is enhanced by the extended room temperature stability, though patients should plan prescription renewals carefully to avoid treatment interruptions that might necessitate dose re-escalation.
UK-Specific Mounjaro vs Wegovy Considerations for Weight Management
The Mounjaro vs Wegovy decision for UK patients involves several region-specific factors that influence treatment outcomes and accessibility. NICE guidance (TA875) specifically recommends Wegovy alongside specialist weight management support, whilst Mounjaro's dual-hormone mechanism offers potentially enhanced metabolic benefits for patients with insulin resistance or prediabetic conditions. NHS availability varies significantly between regions, making private prescription through registered pharmacies like EverydayMeds a reliable alternative for consistent access to either treatment option.
UK prescribing patterns show both treatments achieving significant success when combined with structured lifestyle interventions, though individual response varies based on genetic factors, concurrent medications, and adherence to dietary modifications. The Mounjaro vs Wegovy choice often depends on your healthcare provider's clinical experience with each medication, your specific metabolic profile, and practical considerations like injection frequency and storage requirements during Britain's variable climate conditions.
Start Your Evidence-Based Weight Management Journey Today
Beginning treatment with either option through EverydayMeds provides access to clinically-proven weight management solutions backed by robust trial evidence and ongoing medical supervision. Our qualified prescribers help determine whether Wegovy's established GLP-1 approach or Mounjaro's innovative dual-hormone targeting aligns best with your individual health profile and weight loss goals. Use discount code FIRST40 for new customers or DOSE25 for returning patients when completing your clinical assessment at https://everydaymeds.co.uk/collections/wegovy. Both treatments represent significant advances in obesity medicine, with your prescriber providing personalised guidance based on current clinical evidence and your specific medical requirements. Remember that successful weight management extends beyond medication alone, requiring commitment to the prescribed reduced-calorie diet and increased physical activity that enhance these treatments' effectiveness.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
